Vitamin D deficiency predicts prostate biopsy outcomes

Adam B. Murphy, Yaw Nyame, Iman K. Martin, William J. Catalona, Courtney M P Hollowell, Robert B. Nadler, James M. Kozlowski, Kent T. Perry, Andre Kajdacsy-Balla, Rick A Kittles

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate-specific antigen and/or digital rectal examination. Experimental Design: Serum 25-hydroxyvitamin D (25-OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25-OH D status and incident prostate cancer, Gleason score, and tumor stage. Results: Among European American (EA) men, there was an association of 25-OH D <12 ng/mL with higher Gleason score≥4+4 [OR, 3.66;95%confidence interval (CI), 1.41-9.50; P=0.008] and tumor stage [stage≥cT2b vs. ≤cT2a, OR, 2.42 (1.14-5.10); P=0.008]. In African American (AA) men, we find increased odds of prostate cancer diagnosis on biopsy with 25-OHD< 20 ng/mL [OR, 2.43 (1.20-4.94); P=0.01]. AA men demonstrated an association between 25-OH D < 12 ng/mL and Gleason ≥ 4+4 [OR, 4.89 (1.59-15.07); P=0.006]. There was an association with tumor stage≥cT2b vs.≤cT2a [OR, 4.22 (1.52-11.74); P= 0.003]. Conclusions: In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AAmen, severe deficiency was positively associated with higher Gleason grade and tumor stage.

Original languageEnglish (US)
Pages (from-to)2289-2299
Number of pages11
JournalClinical Cancer Research
Volume20
Issue number9
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

Vitamin D Deficiency
Prostate
Biopsy
African Americans
Prostatic Neoplasms
Vitamin D
Neoplasms
Digital Rectal Examination
Neoplasm Grading
Urology
Prostate-Specific Antigen
Serum
Research Design
Logistic Models
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Murphy, A. B., Nyame, Y., Martin, I. K., Catalona, W. J., Hollowell, C. M. P., Nadler, R. B., ... Kittles, R. A. (2014). Vitamin D deficiency predicts prostate biopsy outcomes. Clinical Cancer Research, 20(9), 2289-2299. https://doi.org/10.1158/1078-0432.CCR-13-3085

Vitamin D deficiency predicts prostate biopsy outcomes. / Murphy, Adam B.; Nyame, Yaw; Martin, Iman K.; Catalona, William J.; Hollowell, Courtney M P; Nadler, Robert B.; Kozlowski, James M.; Perry, Kent T.; Kajdacsy-Balla, Andre; Kittles, Rick A.

In: Clinical Cancer Research, Vol. 20, No. 9, 01.05.2014, p. 2289-2299.

Research output: Contribution to journalArticle

Murphy, AB, Nyame, Y, Martin, IK, Catalona, WJ, Hollowell, CMP, Nadler, RB, Kozlowski, JM, Perry, KT, Kajdacsy-Balla, A & Kittles, RA 2014, 'Vitamin D deficiency predicts prostate biopsy outcomes', Clinical Cancer Research, vol. 20, no. 9, pp. 2289-2299. https://doi.org/10.1158/1078-0432.CCR-13-3085
Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CMP, Nadler RB et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clinical Cancer Research. 2014 May 1;20(9):2289-2299. https://doi.org/10.1158/1078-0432.CCR-13-3085
Murphy, Adam B. ; Nyame, Yaw ; Martin, Iman K. ; Catalona, William J. ; Hollowell, Courtney M P ; Nadler, Robert B. ; Kozlowski, James M. ; Perry, Kent T. ; Kajdacsy-Balla, Andre ; Kittles, Rick A. / Vitamin D deficiency predicts prostate biopsy outcomes. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 9. pp. 2289-2299.
@article{e7ed2e089fe746088b0c3778eccede9b,
title = "Vitamin D deficiency predicts prostate biopsy outcomes",
abstract = "Purpose: The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate-specific antigen and/or digital rectal examination. Experimental Design: Serum 25-hydroxyvitamin D (25-OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25-OH D status and incident prostate cancer, Gleason score, and tumor stage. Results: Among European American (EA) men, there was an association of 25-OH D <12 ng/mL with higher Gleason score≥4+4 [OR, 3.66;95{\%}confidence interval (CI), 1.41-9.50; P=0.008] and tumor stage [stage≥cT2b vs. ≤cT2a, OR, 2.42 (1.14-5.10); P=0.008]. In African American (AA) men, we find increased odds of prostate cancer diagnosis on biopsy with 25-OHD< 20 ng/mL [OR, 2.43 (1.20-4.94); P=0.01]. AA men demonstrated an association between 25-OH D < 12 ng/mL and Gleason ≥ 4+4 [OR, 4.89 (1.59-15.07); P=0.006]. There was an association with tumor stage≥cT2b vs.≤cT2a [OR, 4.22 (1.52-11.74); P= 0.003]. Conclusions: In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AAmen, severe deficiency was positively associated with higher Gleason grade and tumor stage.",
author = "Murphy, {Adam B.} and Yaw Nyame and Martin, {Iman K.} and Catalona, {William J.} and Hollowell, {Courtney M P} and Nadler, {Robert B.} and Kozlowski, {James M.} and Perry, {Kent T.} and Andre Kajdacsy-Balla and Kittles, {Rick A}",
year = "2014",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-13-3085",
language = "English (US)",
volume = "20",
pages = "2289--2299",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Vitamin D deficiency predicts prostate biopsy outcomes

AU - Murphy, Adam B.

AU - Nyame, Yaw

AU - Martin, Iman K.

AU - Catalona, William J.

AU - Hollowell, Courtney M P

AU - Nadler, Robert B.

AU - Kozlowski, James M.

AU - Perry, Kent T.

AU - Kajdacsy-Balla, Andre

AU - Kittles, Rick A

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Purpose: The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate-specific antigen and/or digital rectal examination. Experimental Design: Serum 25-hydroxyvitamin D (25-OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25-OH D status and incident prostate cancer, Gleason score, and tumor stage. Results: Among European American (EA) men, there was an association of 25-OH D <12 ng/mL with higher Gleason score≥4+4 [OR, 3.66;95%confidence interval (CI), 1.41-9.50; P=0.008] and tumor stage [stage≥cT2b vs. ≤cT2a, OR, 2.42 (1.14-5.10); P=0.008]. In African American (AA) men, we find increased odds of prostate cancer diagnosis on biopsy with 25-OHD< 20 ng/mL [OR, 2.43 (1.20-4.94); P=0.01]. AA men demonstrated an association between 25-OH D < 12 ng/mL and Gleason ≥ 4+4 [OR, 4.89 (1.59-15.07); P=0.006]. There was an association with tumor stage≥cT2b vs.≤cT2a [OR, 4.22 (1.52-11.74); P= 0.003]. Conclusions: In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AAmen, severe deficiency was positively associated with higher Gleason grade and tumor stage.

AB - Purpose: The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate-specific antigen and/or digital rectal examination. Experimental Design: Serum 25-hydroxyvitamin D (25-OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25-OH D status and incident prostate cancer, Gleason score, and tumor stage. Results: Among European American (EA) men, there was an association of 25-OH D <12 ng/mL with higher Gleason score≥4+4 [OR, 3.66;95%confidence interval (CI), 1.41-9.50; P=0.008] and tumor stage [stage≥cT2b vs. ≤cT2a, OR, 2.42 (1.14-5.10); P=0.008]. In African American (AA) men, we find increased odds of prostate cancer diagnosis on biopsy with 25-OHD< 20 ng/mL [OR, 2.43 (1.20-4.94); P=0.01]. AA men demonstrated an association between 25-OH D < 12 ng/mL and Gleason ≥ 4+4 [OR, 4.89 (1.59-15.07); P=0.006]. There was an association with tumor stage≥cT2b vs.≤cT2a [OR, 4.22 (1.52-11.74); P= 0.003]. Conclusions: In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AAmen, severe deficiency was positively associated with higher Gleason grade and tumor stage.

UR - http://www.scopus.com/inward/record.url?scp=84899765304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899765304&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-3085

DO - 10.1158/1078-0432.CCR-13-3085

M3 - Article

VL - 20

SP - 2289

EP - 2299

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -